Scientific publications

Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma

Marta Santisteban (1), José Luis Pérez-Gracia [SP] (1), Jaime Ceballos (1), Isabel Vivas [SP] (2) and Jesús García-Foncillas (1)
(1) Medical Oncology Department, Clínica Universitaria de Navarra, Avda. Pío XII, 36, ES-31008 Pamplona, Spain
(2) Radiology Department, Clínica Universitaria de Navarra, Pamplona, Spain

Magazine: Clinical and Translational Oncology

Date: Jun 1, 2008

Radiology [SP] Medical Oncology

We report a case of hormone-refractory prostate cancer (HRPC) treated with oxaliplatin plus gemcitabine in a third-line schedule after liver progression, with an excellent clinical, biochemical and radiological response and with an acceptable tolerance. Prior chemotherapy regimens included docetaxel plus estramustine and oral etoposide.

To our knowledge, this is the first report that shows this approach in an HRPC patient.

CITATION  Clin Transl Oncol. 2008 Jun;10(6):372-4.

you maybe interested

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra